Collegium Pharmaceutical, Inc. (COLL)

Every figure this model derived for COLL, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,643,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 129,467,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 608,014,000 AssetsCurrent 2026-06-30
current liabilities 589,861,000 LiabilitiesCurrent 2026-06-30
equity 311,909,000 StockholdersEquity 2026-06-30
interest expense 76,440,000 InterestExpenseNonoperating 2026-06-30
ocf 329,922,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 808,208,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 44,928,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up COLL on one particular measure came for.

RatioValue
cash operating margin25.56
current ratio1.03
current ratio reported1.03
dilution pct-1.79
ebit cagr55.92
ebit yoy21.35
fcf margin40.62
growth cv1.12
interest cover2.06
operating margin19.48
owner earnings margin35.06
revenue growth14.31
revenue growth per share16.4
roic68.17
rule of 4033.79
sbc pct revenue5.56

What to be careful about

What this model itself distrusts about COLL's figures. Written by the derivation as it ran, not added afterwards.